Abstract: Epidermolysis bullosa (EB) is caused by mutations in the COL7A1 gene encoding type VII collagen. EB comprises a phenotypically diverse group of inherited blistering diseases that affect the skin, and possibly mucous membranes and other organs A number of therapeutic strategies have been explored for managing the treatment of EB, such as (i) surgery, (ii) chemotherapy, (iii) use of collagenase activity inhibitors, (iv) use of antibiotics, (v) use of anti-inflammatory compound, (vi) cell therapies, (viii) protein therapy as well as (ix) gene therapy. Gene therapy of EB aimed to provide therapeutic benefit through manipulation of DNA or RNA. Anti-sense therapy targeting specific exons have been described, such as targeting exons 73 and 80. However, this kind of therapeutic strategy had to be improved as regards its pharmaceutical compliance.